By
Drug Target Review2024-06-06T13:00:41
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T09:00:00Z
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2026-07-09T12:00:00Z
2026-07-07T12:00:00Z
2026-05-25T07:00:00
Contributor Professor Neville Sanjana
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2023-02-23T14:02:18
Sponsored by bit.bio
2024-01-24T12:52:38
Sponsored by BellBrook Labs
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2023-02-03T13:56:13
Sponsored by Leica Microsystems
Site powered by Webvision Cloud